Circulating progranulin as a biomarker for neurodegenerative diseases

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Progranulin is a growth factor involved in the regulation of multiple processes including tumorigenesis, wound repair, development, and inflammation. The recent discovery that mutations in the gene encoding for progranulin (GRN) cause frontotemporal lobar degeneration (FTLD), and other neurodegenerative diseases leading to dementia, has brought renewed interest in progranulin and its functions in the central nervous system. GRN null mutations cause protein haploinsufficiency, leading to a significant decrease in progranulin levels that can be detected in plasma, serum and cerebrospinal fluid (CSF) of mutation carriers. The dosage of circulating progranulin sped up the identification of GRN mutations thus favoring genotype-phenotype correlation studies. Researchers demonstrated that, in GRN null mutation carriers, the shortage of progranulin invariably precedes clinical symptoms and thus mutation carriers are “captured” regardless of their disease status. GRN is a particularly appealing gene for drug targeting, in the way that boosting its expression may be beneficial for mutation carriers, preventing or delaying the onset of GRN-related neurodegenerative diseases. Physiological regulation of progranulin expression level is only partially known. Progranulin expression reflects mutation status and, intriguingly, its levels can be modulated by some additional factor (i.e. genetic background; drugs). Thus, factors increasing the production and secretion of progranulin from the normal gene are promising potential therapeutic avenues. In conclusion, peripheral progranulin is a nonintrusive highly accurate biomarker for early identification of mutation carriers and for monitoring future treatments that might boost the level of this protein.

Original languageEnglish
Pages (from-to)180-190
Number of pages11
JournalAmerican Journal of Neurodegenerative Diseases
Volume1
Issue number2
Publication statusPublished - Aug 15 2012

Fingerprint

Neurodegenerative Diseases
Biomarkers
Mutation
Frontotemporal Lobar Degeneration
Haploinsufficiency
Gene Targeting
Genetic Association Studies
Drug Delivery Systems
Genes
Cerebrospinal Fluid
Dementia
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Proteins
Central Nervous System
Research Personnel
Inflammation
Wounds and Injuries
Therapeutics
Serum

Keywords

  • Blood
  • CSF
  • Cut-off
  • Dementia
  • Expression
  • Frontotemporal
  • GRN
  • Haploinsufficiency
  • Modulator
  • Progranulin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

@article{5c8af738877243b480470910f3a8fe06,
title = "Circulating progranulin as a biomarker for neurodegenerative diseases",
abstract = "Progranulin is a growth factor involved in the regulation of multiple processes including tumorigenesis, wound repair, development, and inflammation. The recent discovery that mutations in the gene encoding for progranulin (GRN) cause frontotemporal lobar degeneration (FTLD), and other neurodegenerative diseases leading to dementia, has brought renewed interest in progranulin and its functions in the central nervous system. GRN null mutations cause protein haploinsufficiency, leading to a significant decrease in progranulin levels that can be detected in plasma, serum and cerebrospinal fluid (CSF) of mutation carriers. The dosage of circulating progranulin sped up the identification of GRN mutations thus favoring genotype-phenotype correlation studies. Researchers demonstrated that, in GRN null mutation carriers, the shortage of progranulin invariably precedes clinical symptoms and thus mutation carriers are “captured” regardless of their disease status. GRN is a particularly appealing gene for drug targeting, in the way that boosting its expression may be beneficial for mutation carriers, preventing or delaying the onset of GRN-related neurodegenerative diseases. Physiological regulation of progranulin expression level is only partially known. Progranulin expression reflects mutation status and, intriguingly, its levels can be modulated by some additional factor (i.e. genetic background; drugs). Thus, factors increasing the production and secretion of progranulin from the normal gene are promising potential therapeutic avenues. In conclusion, peripheral progranulin is a nonintrusive highly accurate biomarker for early identification of mutation carriers and for monitoring future treatments that might boost the level of this protein.",
keywords = "Blood, CSF, Cut-off, Dementia, Expression, Frontotemporal, GRN, Haploinsufficiency, Modulator, Progranulin",
author = "Roberta Ghidoni and Anna Paterlini and Luisa Benussi",
year = "2012",
month = "8",
day = "15",
language = "English",
volume = "1",
pages = "180--190",
journal = "American Journal of Neurodegenerative Diseases",
issn = "2165-591X",
publisher = "e-Century Publishing Corporation",
number = "2",

}

TY - JOUR

T1 - Circulating progranulin as a biomarker for neurodegenerative diseases

AU - Ghidoni, Roberta

AU - Paterlini, Anna

AU - Benussi, Luisa

PY - 2012/8/15

Y1 - 2012/8/15

N2 - Progranulin is a growth factor involved in the regulation of multiple processes including tumorigenesis, wound repair, development, and inflammation. The recent discovery that mutations in the gene encoding for progranulin (GRN) cause frontotemporal lobar degeneration (FTLD), and other neurodegenerative diseases leading to dementia, has brought renewed interest in progranulin and its functions in the central nervous system. GRN null mutations cause protein haploinsufficiency, leading to a significant decrease in progranulin levels that can be detected in plasma, serum and cerebrospinal fluid (CSF) of mutation carriers. The dosage of circulating progranulin sped up the identification of GRN mutations thus favoring genotype-phenotype correlation studies. Researchers demonstrated that, in GRN null mutation carriers, the shortage of progranulin invariably precedes clinical symptoms and thus mutation carriers are “captured” regardless of their disease status. GRN is a particularly appealing gene for drug targeting, in the way that boosting its expression may be beneficial for mutation carriers, preventing or delaying the onset of GRN-related neurodegenerative diseases. Physiological regulation of progranulin expression level is only partially known. Progranulin expression reflects mutation status and, intriguingly, its levels can be modulated by some additional factor (i.e. genetic background; drugs). Thus, factors increasing the production and secretion of progranulin from the normal gene are promising potential therapeutic avenues. In conclusion, peripheral progranulin is a nonintrusive highly accurate biomarker for early identification of mutation carriers and for monitoring future treatments that might boost the level of this protein.

AB - Progranulin is a growth factor involved in the regulation of multiple processes including tumorigenesis, wound repair, development, and inflammation. The recent discovery that mutations in the gene encoding for progranulin (GRN) cause frontotemporal lobar degeneration (FTLD), and other neurodegenerative diseases leading to dementia, has brought renewed interest in progranulin and its functions in the central nervous system. GRN null mutations cause protein haploinsufficiency, leading to a significant decrease in progranulin levels that can be detected in plasma, serum and cerebrospinal fluid (CSF) of mutation carriers. The dosage of circulating progranulin sped up the identification of GRN mutations thus favoring genotype-phenotype correlation studies. Researchers demonstrated that, in GRN null mutation carriers, the shortage of progranulin invariably precedes clinical symptoms and thus mutation carriers are “captured” regardless of their disease status. GRN is a particularly appealing gene for drug targeting, in the way that boosting its expression may be beneficial for mutation carriers, preventing or delaying the onset of GRN-related neurodegenerative diseases. Physiological regulation of progranulin expression level is only partially known. Progranulin expression reflects mutation status and, intriguingly, its levels can be modulated by some additional factor (i.e. genetic background; drugs). Thus, factors increasing the production and secretion of progranulin from the normal gene are promising potential therapeutic avenues. In conclusion, peripheral progranulin is a nonintrusive highly accurate biomarker for early identification of mutation carriers and for monitoring future treatments that might boost the level of this protein.

KW - Blood

KW - CSF

KW - Cut-off

KW - Dementia

KW - Expression

KW - Frontotemporal

KW - GRN

KW - Haploinsufficiency

KW - Modulator

KW - Progranulin

UR - http://www.scopus.com/inward/record.url?scp=84980053522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980053522&partnerID=8YFLogxK

M3 - Review article

VL - 1

SP - 180

EP - 190

JO - American Journal of Neurodegenerative Diseases

JF - American Journal of Neurodegenerative Diseases

SN - 2165-591X

IS - 2

ER -